Serum chloride and the response to hydrochlorothiazide in patients with acute heart failure: a post-hoc analysis from the CLOROTIC trial
Revista Española de Cardiología (English Edition) · 2026-11 · 79 (11) · 911-922
DOI: 10.1016/j.rec.2026.04.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Revista Española de Cardiología (English Edition), 2026-11. Verfasst von David García-Escrivá und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Interna, Consorcio Hospital General Universitario de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Heart Failure, Chlorides. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Sociedad Española de Medicina Interna.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Hypochloremia is associated with worse prognosis and diuretic resistance in acute heart failure (AHF). This study investigated whether serum chloride is associated with the efficacy and safety of hydrochlorothiazide in patients with AHF. METHODS: This post-hoc analysis included all 230 patients from the CLOROTIC (Safety and efficacy of the combination of loop with thiazide-type diuretics in patients with decompensated heart failure) trial, randomized to oral hydrochlorothiazide or placebo in addition to intravenous furosemide. The impact of baseline serum chloride on the treatment effect of hydrochlorothiazide on the main trial endpoints was assessed. RESULTS: At baseline, hypochloremia ( 106 mmol/L) were observed in 17% and 9% of patients, respectively. The effect of hydrochlorothiazide was more pronounced in patients with hypo- or normochloremia than in those with hyperchloremia for several efficacy endpoints (weight loss at 72 or 96hours, 24-hour diuresis, and diuresis per milligram of furosemide); only weight loss at 72hours showed a significant interaction (P = .02). However, when baseline chloride was modeled as a continuous variable, no significant interaction was observed with primary or secondary efficacy endpoints. Similarly, no significant interaction was found between serum chloride and the effect of hydrochlorothiazide on mortality or rehospitalization. Regarding safety endpoints, baseline hypochloremia was significantly associated with an increased risk of hypokalemia (potassium< 3.5 mmol/L) in patients allocated to hydrochlorothiazide (P = .029), with no significant interaction between hydrochlorothiazide and baseline chloride for the other safety outcomes. CONCLUSIONS: In patients with AHF, the addition of hydrochlorothiazide to loop diuretics enhances decongestion regardless of the baseline serum chloride. (ClinicalTrials.gov: NCT01647932; EudraCT Number: 2013-001852-36).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Medicina Interna, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
- Servicio de Cardiología, Hospital Clínico de Valencia, INCLIVA, Valencia, Spain; Departamento de Medicina, Universidad de Valencia, Valencia, Spain.
- Servicio de Medicina Interna, Hospital Universitario de Getafe, Getafe, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Salud y Deportes, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.
- Unidad de Insuficiencia Cardiaca, Servicio de Medicina Interna, Hospital Universitari Arnau de Villanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lérida, Spain.
- Servicio de Medicina Interna, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Instituto de Investigación en Salud de Aragón (IIS Aragón), Zaragoza, Spain.
- Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain; Facultad de Medicina, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria…
Förderung
- Sociedad Española de Medicina Interna
Zitieren
APA
García-Escrivá, D., Pérez-Silvestre, J., Núñez, J., Casado, J., Morales-Rull, J. L., Sánchez-Marteles, M., Conde-Martel, A., Llàcer, P., Salamanca-Bautista, P., Plasín, M. Á., Cerqueiro, J. M., Gil, P., Manzano, L., Formiga, F., Trullàs, J. C., & CLOROTIC trial investigators (2026). Serum chloride and the response to hydrochlorothiazide in patients with acute heart failure: a post-hoc analysis from the CLOROTIC trial. Revista Española de Cardiología (English Edition), 79(11), 911-922. https://doi.org/10.1016/j.rec.2026.04.006
Vancouver
García-Escrivá D, Pérez-Silvestre J, Núñez J, Casado J, Morales-Rull JL, Sánchez-Marteles M, et al. Serum chloride and the response to hydrochlorothiazide in patients with acute heart failure: a post-hoc analysis from the CLOROTIC trial. Revista Española de Cardiología (English Edition). 2026;79(11):911-922. doi:10.1016/j.rec.2026.04.006
BibTeX
@article{GarcaEscriv2026,
author = {García-Escrivá, David and Pérez-Silvestre, José and Núñez, Julio and Casado, Jesús and Morales-Rull, José Luís and Sánchez-Marteles, Marta and Conde-Martel, Alicia and Llàcer, Pau and Salamanca-Bautista, Prado and Plasín, Miguel Ángel and Cerqueiro, José Manuel and Gil, Paloma and Manzano, Luís and Formiga, Francesc and Trullàs, Joan Carles and CLOROTIC trial investigators, CLOROTIC trial investigators},
title = {Serum chloride and the response to hydrochlorothiazide in patients with acute heart failure: a post-hoc analysis from the CLOROTIC trial},
journal = {Revista Española de Cardiología (English Edition)},
year = {2026},
volume = {79},
number = {11},
pages = {911--922},
doi = {10.1016/j.rec.2026.04.006}
}
EUVIMED